{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:54:25Z","timestamp":1778223265376,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cyclophosphamide is a commonly used chemotherapeutic agent in hematopoietic stem cell transplantation (HSCT), but its use can lead to adverse effects such as hemorrhagic cystitis (HC) and electrolyte disturbances, including hyponatremia. While standard hydration protocols are used to mitigate these risks, the optimal regimen remains unclear. This study explores the impact of a restrictive hydration regimen on HC incidence and electrolyte imbalances in patients undergoing high-dose cyclophosphamide treatment as part of HSCT conditioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted at Amsterdam UMC, including patients who received high-dose cyclophosphamide as part of HSCT between 2016 and 2024. Patients were grouped based on hydration protocols: an original regimen (5 L of NaCl 0.45%\/dextrose 2.5% per day) and a new restrictive regimen (1.5 L\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day of 0.65% NaCl). The primary endpoint was the incidence of HC, while secondary endpoints included sodium and potassium changes, fluid overload (measured by furosemide use), and clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HC occurred in 10\/386 (2.6%) patients in the original protocol and 1\/69 (1.4%) in the restrictive protocol (odds ratio [95% confidence interval]: 0.55 [0.03\u20132.96],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.57). Clinically relevant hyponatremia was less common with the restrictive regimen (1.4%) than with the original protocol (4.4%), though the difference was not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.27). On the other hand, patients receiving the restrictive regimen showed more clinically relevant hypokalemia (8.7% vs 5.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.28). Fluid overload, as indicated by furosemide use, was lower in the restrictive group albeit not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective single-center cohort, we did not observe a higher incidence of HC or electrolyte imbalances with a restrictive hydration regimen compared to the original regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10465-9","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:05:14Z","timestamp":1771833914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Restrictive versus standard hyperhydration during high-dose cyclophosphamide for hematopoietic stem cell transplantation: a retrospective cohort study"],"prefix":"10.1007","volume":"34","author":[{"given":"R. J.","family":"Boosman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Crul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Heerma van Voss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"10465_CR1","unstructured":"Summary of Product Characteristics (n.d.) Cyclofosfamide 500 mg, poeder voor oplossing voor injectie\/infusie. Available online:  https:\/\/geneesmiddeleninformatiebank.nl . Accessed on 28 April 2025"},{"issue":"1","key":"10465_CR2","first-page":"247","volume":"150","author":"MV Souza-Fiho","year":"1997","unstructured":"Souza-Fiho MV, Lima MV, Pompeu MM, Ballejo G, Cunha FQ, Ribeiro RA (1997) Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Am J Pathol 150(1):247\u2013256","journal-title":"Am J Pathol"},{"issue":"5","key":"10465_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10565-006-0078-0","volume":"23","author":"A Korkmaz","year":"2007","unstructured":"Korkmaz A, Topal T, Oter S (2007) Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 23(5):303\u2013312","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"10465_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.7326\/0003-4819-82-1-84","volume":"82","author":"PS Schein","year":"1975","unstructured":"Schein PS, Winokur SH (1975) Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med 82(1):84\u201395","journal-title":"Ann Intern Med"},{"issue":"7","key":"10465_CR5","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1200\/JCO.1993.11.7.1306","volume":"11","author":"JM Vose","year":"1993","unstructured":"Vose JM, Reed EC, Pippert GC, Anderson JR, Bierman PJ, Kessinger A et al (1993) Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 11(7):1306\u20131310","journal-title":"J Clin Oncol"},{"issue":"7","key":"10465_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/bju.12291","volume":"112","author":"H Payne","year":"2013","unstructured":"Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C et al (2013) Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int 112(7):885\u2013897","journal-title":"BJU Int"},{"issue":"7","key":"10465_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jtct.2022.05.012","volume":"28","author":"D Ngo","year":"2022","unstructured":"Ngo D, Samuels D, Chen J, Koller PB, Al Malki MM (2022) A clinical review of the different strategies to minimize hemorrhagic cystitis associated with the use of post-transplantation cyclophosphamide in an allogeneic transplant. Transplant Cell Ther 28(7):349\u2013354","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10465_CR8","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1038\/s41409-021-01364-0","volume":"56","author":"S Mac","year":"2021","unstructured":"Mac S, Ngo D, Yang D, Chen J, Ali H, Arslan S et al (2021) Use of high-dose Mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. Bone Marrow Transplant 56(10):2464\u20132470","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10465_CR9","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.bbmt.2020.04.028","volume":"26","author":"M Arango","year":"2020","unstructured":"Arango M, Cardona D (2020) Hemorrhagic cystitis after haploidentical transplantation with post-transplantation cyclophosphamide: protective effect of MESNA continuous infusion. Biol Blood Marrow Transplant 26(8):1492\u20131496","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10465_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/1097-0142(197402)33:2<483::AID-CNCR2820330224>3.0.CO;2-P","volume":"33","author":"RA Defronzo","year":"1974","unstructured":"Defronzo RA, Colvin M, Braine H, Robertson GL, Davis PJ (1974) Cyclophosphamide and the kidney. Cancer 33(2):483\u2013491","journal-title":"Cancer"},{"issue":"6","key":"10465_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.7326\/0003-4819-78-6-861","volume":"78","author":"RA DeFronzo","year":"1973","unstructured":"DeFronzo RA, Braine H, Colvin M, Davis PJ (1973) Water intoxication in man after cyclophosphamide therapy. Time course and relation to drug activation. Ann Intern Med 78(6):861\u2013869","journal-title":"Ann Intern Med"},{"issue":"5","key":"10465_CR12","first-page":"341","volume":"4","author":"T Berghmans","year":"1996","unstructured":"Berghmans T (1996) Hyponatremia related to medical anticancer treatment. Support Care Cancer 4(5):341\u2013350","journal-title":"Support Care Cancer"},{"issue":"3","key":"10465_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/1097-0142(197909)44:3<896::AID-CNCR2820440316>3.0.CO;2-9","volume":"44","author":"PJ Harlow","year":"1979","unstructured":"Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E (1979) A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 44(3):896\u2013898","journal-title":"Cancer"},{"key":"10465_CR14","doi-asserted-by":"crossref","unstructured":"McNab S, Ware RS, Neville KA, Choong K, Coulthard MG, Duke T et al (2014) Isotonic versus hypotonic solutions for maintenance intravenous fluid administration in children. Cochrane Database Syst Rev 2014(12):CD009457","DOI":"10.1002\/14651858.CD009457.pub2"},{"issue":"12","key":"10465_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00467-005-1933-6","volume":"20","author":"ML Moritz","year":"2005","unstructured":"Moritz ML, Ayus JC (2005) Preventing neurological complications from dysnatremias in children. Pediatr Nephrol 20(12):1687\u20131700","journal-title":"Pediatr Nephrol"},{"key":"10465_CR16","doi-asserted-by":"crossref","unstructured":"Armon K, Riordan A, Playfor S, Millman G, Khader A (2008) Hyponatraemia and hypokalaemia during intravenous fluid administration. Arch Dis Child 93(4):285\u2013287.Paediatric Research S","DOI":"10.1136\/adc.2006.093823"},{"key":"10465_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2023.11.039","volume":"212","author":"JH Yong","year":"2024","unstructured":"Yong JH, Mai AS, Mateti\u0107 A, Elbadawi A, Elgendy IY, Lopez-Fernandez T et al (2024) Cardiovascular risk in patients with hematological malignancies: a systematic review and meta-analysis. Am J Cardiol 212:80\u2013102","journal-title":"Am J Cardiol"},{"key":"10465_CR18","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program (2017) Common toxicity criteria for adverse events v5.0 (CTCAE); Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed on 8 July 2024"},{"key":"10465_CR19","unstructured":"Summary of Product Characteristics (n.d.) Furosemide 40 mg, tabletten. Available online: https:\/\/geneesmiddeleninformatiebank.nl. Accessed on 28 April 2025"},{"issue":"4","key":"10465_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/1043454214532024","volume":"31","author":"D Robinson","year":"2014","unstructured":"Robinson D, Schulz G, Langley R, Donze K, Winchester K, Rodgers C (2014) Evidence-based practice recommendations for hydration in children and adolescents with cancer receiving intravenous cyclophosphamide. J Pediatr Oncol Nurs 31(4):191\u2013199","journal-title":"J Pediatr Oncol Nurs"},{"issue":"6","key":"10465_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/bjc.1984.252","volume":"50","author":"JM Hows","year":"1984","unstructured":"Hows JM, Mehta A, Ward L, Woods K, Perez R, Gordon MY et al (1984) Comparison of Mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer 50(6):753\u2013756","journal-title":"Br J Cancer"},{"issue":"1","key":"10465_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13613-021-00851-3","volume":"11","author":"N Van Regenmortel","year":"2021","unstructured":"Van Regenmortel N, Moers L, Langer T, Roelant E, De Weerdt T, Caironi P et al (2021) Fluid-induced harm in the hospital: look beyond volume and start considering sodium. From physiology towards recommendations for daily practice in hospitalized adults. Ann Intensive Care 11(1):79","journal-title":"Ann Intensive Care"},{"issue":"21","key":"10465_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","volume":"342","author":"HJ Adrogu\u00e9","year":"2000","unstructured":"Adrogu\u00e9 HJ, Madias NE (2000) Hyponatremia. N Engl J Med 342(21):1581\u20131589. https:\/\/doi.org\/10.1056\/NEJM200005253422107","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10465-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:13:35Z","timestamp":1778174015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10465-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10465"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10465-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local institutional review board of the Amsterdam UMC (study number: 2024.0125). The board determined that formal ethical approval and informed consent were not required due to the retrospective design. This research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}